Acer Therapeutics rises after gaining EU's 'orphan drug' tag

MindMaze Therapeutics Holding SA

12/08/2022 14:45

** Shares of Acer Therapeutics Inc  ACER.O  gain 5.4% to
$1.56 
    ** Co and its partner Relief Therapeutics Holding SA
 RLFB.S  say European Commission grants 'orphan drug'
designation to its experimental drug ACER-001 for treating maple
syrup urine disease (MSUD)  urn:newsml:reuters.com:*:nGNX9BKS5F
    ** MSUD is a rare genetic disorder that occurs when the body
cannot breakdown certain parts of proteins
    ** Benefits of the orphan drug tag include potential for up
to 10-year EU market exclusivity upon regulatory approval of the
therapy
    ** Including session's gain, stock down ~32% this year

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))